Hong Kong Stock Exchange pursues international biotechnology companies as part of broader Asian market positioning strategy. Insilico Medicine’s December public offering marked key milestone, with French firm TheraVectys reportedly evaluating potential Hong Kong listing.
Source: FinanceAsia Read Full Story